RareCyte, a life sciences company offering advanced Precision Biology platforms, including instruments, reagents, software, and services, announced the completion of $20 million in funding from new and existing investors. New investor Forest Road has joined existing investors Arboretum Ventures and F-Prime Capital (which co-led the round) and investors HealthQuest Capital, 5AM Ventures, Agilent Technologies, Company founder Ron Seubert, Sheatree capital, and GKCC LLC.
This funding is expected to enable the company to drive an expansion of the successful Orion Spatial Biology platform including commercializing new multiplex assays, reagent products, and software applications.
This funding is also going to support the expansion of RareCyte’s Precision Biology Services, including spatial biology and liquid biopsy assays, utilizing its Seattle, WA-based labs and scientific personnel, which perform under CLIA and ISO 13485 certifications. The new funding will amplify global commercial expansion in regions outside the US.
The RareCyte Orion platform was adopted and recognized worldwide as the only spatial biology platform that addresses the translational market requirements from discovery applications to clinical trial support. And Orion enables rapid sub-cellular scanning and analysis of tissue and blood samples for up to 20 biomarkers with turn-around times that will support large cohort studies. Exquisite sensitivity and a broad dynamic range support comprehensive cellular phenotyping utilized by researchers and drug developers to determine mechanism of action for candidate therapeutics.
The Orion platform includes a wide array of validated biomarkers allowing immediate access by researchers and clinicians to advance studies across immuno-oncology, immunology, neurology, infectious disease, and other critical disease areas.
KEY QUOTES:
“We are thrilled to join a world-class group of investors and partner with the RareCyte team to drive towards realizing the promise of Precision Biology for researchers and patients”.
- Bill Burkoth, Managing Partner for Life Sciences at Forest Road
“We are honored to have Forest Road join an outstanding group of investors led by Arboretum Ventures and F-Prime Capital. This funding will allow RareCyte to accelerate the development of our broad menu of Spatial Biology assays, applications, and software products to benefit our customers worldwide.”
- Joe Victor, RareCyte President and CEO
